Immunotherapy

Indigenous Summer Studentships

11/25/2022

Excerpt from the Press Release: The goal of the BioCanRx Indigenous Student Summer InternshipProgram is to provide Indigenous undergraduate university or college students with meaningful hands-on research or policy experience in the area of cancer. This is accomplished through internships with research groups at post-secondary institutions across Canada or with partnering organization, Canadian Partnership Against…

Read More

EdiGene Announces Completion of Last Patient Dosing in Phase I Clinical Trial of ET-01, its Investigational Gene-editing Hematopoietic Stem Cell Therapy for Transfusion Dependent β-thalassemia

11/23/2022

Excerpt from the Press Release: BEIJING & WALTHAM, Mass.–(BUSINESS WIRE)–EdiGene, Inc., a global, clinical-stage company focused on translating gene-editing technologies into transformative genetic medicines for patients with significant unmet medical needs, announced it had completed the last patient dosing in Phase I clinical trial of ET-01, its investigational gene-editing hematopoietic stem cell therapy for transfusion…

Read More

Candel Therapeutics Announces Oral Presentation of Updated Data from its Phase 1 Clinical Trial of CAN-3110 in 41 Patients with Recurrent High-Grade Glioma at the Society for Neuro-Oncology 27th Annual Meeting

11/23/2022

CAN-3110 designed to limit replication and promote anti-tumor response to tumor cells while protecting healthy tissue No dose-limiting toxicities observed in 41 patients with recurrent high-grade glioma (rHGG) Median overall survival was 11.6 months after a single injection of CAN-3110 in patients with rHGG; one patient achieved a complete response lasting more than one year…

Read More

Agenus Data at CTOS 2022 Highlight Durable Clinical Responses of Botensilimab / Balstilimab Combination in Advanced Sarcoma

11/22/2022

Overall response rate (ORR) of 46% and disease control rate (DCR) of 69% in heavily pre-treated patients who have received a median of 3 prior lines of therapy Patient responses include sarcoma subtypes that historically do not respond to immunotherapy, including responses in 3 of 4 patients with visceral angiosarcoma 67% of patient responses have…

Read More

Revelation Biosciences Inc. Announces Future Clinical Development Plans Based on Recent Biomarker Analysis and Significant Reduction in New Collagen Deposition (Fibrosis) in Preclinical Model

11/22/2022

Excerpt from the Press Release: SAN DIEGO, Calif.–(BUSINESS WIRE)–Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced that recently completed exploratory biomarker analysis has confirmed clinical development plans for REVTx-300 in the…

Read More

Corner Therapeutics Debuts with Data Presentation on its Dendritic Cell Hyperactivation Platform at the Society for Immunotherapy of Cancer (SITC) Annual Meeting

11/17/2022

Excerpt from the Press Release: WATERTOWN, Mass.–(BUSINESS WIRE)–Corner Therapeutics, a biotechnology company exploiting a new scientific paradigm to boost memory T cell responses to disease, debuts today with presentation of data on its dendritic cell hyperactivation (hDC) platform at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), taking place November 8-12,…

Read More

Immune-Onc Therapeutics to Present Trial in Progress Poster for Phase 1 Study of IO-202 in Patients with Advanced Solid Tumors at the Society for Immunotherapy of Cancer Annual Meeting

11/15/2022

The multicenter Phase 1 study is currently enrolling and evaluating IO-202 as monotherapy and in combination with an anti-PD-1 for the treatment of solid tumors Excerpt from the Press Release: PALO ALTO, Calif.–(BUSINESS WIRE)–Immune-Onc Therapeutics, Inc. (“Immune-Onc”), a private, clinical-stage cancer immunotherapy company developing novel biotherapeutics targeting myeloid checkpoints, today announced that it will present…

Read More

Asher Bio Presents New Preclinical Data at SITC 2022 Further Supporting Advancement of AB248 and AB821 as Highly Differentiated Cis-targeted Cancer Immunotherapies

11/14/2022

— AB248 demonstrates non-clinical activity and safety profile suggesting its potential as a best-in-class IL-2 — — AB821 shows differentiated anti-tumor activity and enhanced bioavailability over wild type IL-21 — — On track to initiate Phase 1 trial of AB248 in 4Q 2022; Plan to file investigational new drug (IND) application for AB821 in 2H…

Read More

Adicet Bio Reports ASH Abstract Data from Ongoing ADI-001 Phase 1 Trial in Relapsed or Refractory Aggressive B-Cell Non-Hodgkin’s Lymphoma (NHL)

11/10/2022

As of the July 15, 2022 ASH abstract data-cut date, ADI-001 demonstrated a 78% overall and complete response rate and sustained durability in patients, including those previously exposed to CAR T therapy 100% ORR and CR rate in four anti-CD19 CAR T relapsed patients ADI-001 continued to demonstrate a favorable safety and tolerability profile Clinical…

Read More

Ardelyx Presents New Data Analyses at Kidney Week 2022, Further Supporting the Clinical Relevance of XPHOZAH® (tenapanor), an Investigational, Phosphate Absorption Inhibitor to Control Serum Phosphorus in Adult Patients with Chronic Kidney Disease on Dialysis

11/09/2022

XPHOZAH monotherapy lowers serum phosphorus with early responders maintaining response with continued treatment XPHOZAH monotherapy meaningfully reduced serum phosphorus in patients with severe hyperphosphatemia XPHOZAH in combination with phosphate binders reduced patients’ interdialytic weight gain compared to binders alone Excerpt from the Press Release: WALTHAM, Mass., Nov. 3, 2022 /PRNewswire/ — Ardelyx, Inc. (Nasdaq: ARDX), a…

Read More